Literature DB >> 8922788

Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa.

J Rello1, P Jubert, J Vallés, A Artigas, M Rué, M S Niederman.   

Abstract

Thirty consecutively intubated patients with pneumonia due to Pseudomonas aeruginosa (cases) were prospectively observed to establish the attributable mortality rate and the prognostic value of APACHE (Acute Physiological and Chronic Health Evaluation) II scores. Four cases did not receive accurate empirical therapy and were excluded from the study. APACHE II scores were calculated within 24 hours of admission (T0), at the time of the diagnosis of pneumonia (T1), and after 72 hours of therapy (T2). The outcomes for these cases (n = 26) were compared with those for matched controls (n = 52) without pneumonia. Six cases died of causes directly related to pneumonia (group D). Two cases whose conditions clinically improved died of cardiac complications, and 18 cases had clinical resolution (group R); however, only 15 of these cases were alive at discharge. The mean APACHE II score at admission was similar (P > .20) for group R, group D, and controls. In contrast, the mean score at T1 (15.40 +/- 6.07 vs. 20.83 +/- 4.66; P < .05) and the mean score at T2 (10.40 +/- 3.57 vs. 25.50 +/- 3.93; P < .01) differed significantly for groups R and D, respectively. The overall observed and predicted mortality rates among cases and controls were 42.3% and 28.1% and 28.8% and 28.7%, respectively, while the attributable mortality rate among cases was estimated to be 13.5% (95% confidence interval, 1.95%-25.04%). We conclude that the attributable mortality rate among intubated patients with pneumonia due to P. aeruginosa is high. The APACHE II score at admission is not useful as a prognostic factor, while progression of organ dysfunction after the onset of pneumonia is an ominous sign.

Entities:  

Mesh:

Year:  1996        PMID: 8922788     DOI: 10.1093/clinids/23.5.973

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures.

Authors:  Pieter Depuydt; Dominique Benoit; Dirk Vogelaers; Geert Claeys; Gerda Verschraegen; Koenraad Vandewoude; Johan Decruyenaere; Stijn Blot
Journal:  Intensive Care Med       Date:  2006-09-16       Impact factor: 17.440

2.  Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.

Authors:  F Luzzaro; E Mantengoli; M Perilli; G Lombardi; V Orlandi; A Orsatti; G Amicosante; G M Rossolini; A Toniolo
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

3.  Risk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first century.

Authors:  Jordi Rello; Bárbara Borgatta; Thiago Lisboa
Journal:  Intensive Care Med       Date:  2013-10-22       Impact factor: 17.440

4.  Modification of dienes mutual inhibition test for epidemiological characterization of Pseudomonas aeruginosa isolates.

Authors:  Erik L Munson; Michael A Pfaller; Gary V Doern
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

5.  The effect of preexisting respiratory co-morbidities on burn outcomes.

Authors:  Laquanda T Knowlin; Lindsay B Stanford; Bruce A Cairns; Anthony G Charles
Journal:  Burns       Date:  2016-10-27       Impact factor: 2.744

Review 6.  Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy".

Authors:  Alberto Sandiumenge; Emili Diaz; Maria Bodí; Jordi Rello
Journal:  Intensive Care Med       Date:  2003-04-02       Impact factor: 17.440

7.  Pseudomonas aeruginosa induces localized immunosuppression during pneumonia.

Authors:  Maureen H Diaz; Ciara M Shaver; John D King; Srinidhi Musunuri; Jeffrey A Kazzaz; Alan R Hauser
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

8.  Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.

Authors:  C Jaccard; N Troillet; S Harbarth; G Zanetti; D Aymon; R Schneider; R Chiolero; B Ricou; J Romand; O Huber; P Ambrosetti; G Praz; D Lew; J Bille; M P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection.

Authors:  Manu Jain; Maskit Bar-Meir; Susanna McColley; Joanne Cullina; Eileen Potter; Cathy Powers; Michelle Prickett; Roopa Seshadri; Borko Jovanovic; Argyri Petrocheilou; John D King; Alan R Hauser
Journal:  Transl Res       Date:  2008-10-31       Impact factor: 7.012

10.  Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity.

Authors:  Christophe Clec'h; Jean-François Timsit; Arnaud De Lassence; Elie Azoulay; Corinne Alberti; Maite Garrouste-Orgeas; Bruno Mourvilier; Gilles Troche; Muriel Tafflet; Olivier Tuil; Yves Cohen
Journal:  Intensive Care Med       Date:  2004-06-09       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.